Advertisement

Topics

ESC 2017: New Xarelto Data Includes Results from Landmark Phase III COMPASS Study

13:00 EDT 23 Aug 2017 | Drug Discovery Development

Both COMPASS and PIONEER AF-PCI are part of the EXPLORER clinical research program for XARELTO.
Contributed Author: 
Johnson & Johnson

Original Article: ESC 2017: New Xarelto Data Includes Results from Landmark Phase III COMPASS Study

NEXT ARTICLE

More From BioPortfolio on "ESC 2017: New Xarelto Data Includes Results from Landmark Phase III COMPASS Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...